Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

What this study is testing ClinicalTrials.gov NCT07056803 ↗

Description as written by the study sponsor.

This real-world, comparative cohort study aims to evaluate the 12-month effectiveness of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2D), with a specific focus on sex-based differences in metabolic response. A total of 212 patients were enrolled and evenly assigned to either oral or subcutaneous semaglutide. The primary outcome was the change in HbA1c, while secondary outcomes included variations in weight, lipid profile, liver function, and hepatic steatosis index. Subcutaneous semaglutide resulted in greater improvements in HbA1c, weight, and LDL cholesterol in men, while women exhibited a more favorable hepatic response. These findings support the need for sex-specific considerations in T2D therapy personalization.

Treatments tested

• Oral semaglutide Drug

  Starting dose 3 mg for a month, followed by 7 mg for a month increased up to 14 mg a month

• subcutaneous semaglutide Drug

  subcutaneous semaglutide can be started at 0,25 mg a week for a month, to be increased at 0,5 mg a week, up to 1 mg a week